Journals / Tüberküloz ve Toraks / 2014 / Cilt: 62 - Sayı: 4

Elevated pleural copeptin levels can distinguish to exudate from transudates

Yüksek plevral copeptin düzeyleri eksüdayı transüdadan ayırabilir

Pages
267–272
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The concentrations of pleural copeptin and typical pleural and serum marker levels were measured in 76 subjects withpleural effusions including 22 transudates caused by congestive heart failure (CHF), and 54 exudates including 18 parapneumonic(PPE), 18 tuberculous pleural effusions (TBPEs), 18 malignant effusions (MPEs).Results: Median pleural fluid copeptin levels were higher in exudates than in transudates (1936 ng/mL and 1313 pg/mL, p value

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Introduction: Copeptin is released simultaneously along witharginine-vasopressine as a result of different stimuli from the neurohypophysis.
📊
Key Findings & Data:Increased blood copeptin levels is associated with poor prognosis inmany diseases.
💡
Conclusion & Impact:The concentrations of pleural copeptin and typical pleural and serum marker levels were measured in 76 subjects withpleural effusions including 22 transudates caused by congestive heart failure (CHF), and 54 exudates including 18 parapneumonic(PPE), 18 tuberculous pleural effusions (TBPEs), 18 malignant effusions (MPEs).Results: Median pleural fluid copeptin levels were higher in exudates than in transudates (1936 ng/mL and 1313 pg/mL, p value
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Introduction: Copeptin is released simultaneously along witharginine-vasopressine as a result of different stimuli from the neurohypophysis. Physiological function of copeptin is still unclear. Increased blood copeptin levels is associated with poor prognosis inmany diseases. Pleural effusion is a common clinical condition. The most common causes of pleural effusions are heart failure, par-apneumonic effusion, pulmonary embolism and malignacy.Tuberculosis is one of the other major causes of pleural effusion in devel-oping countries. In this study, we aimed to assess whether pleural copeptin level may be a new discriminative biomarker for exudatesand transudates pleural effusions.Materials and Methods: Research was done at Recep Tayyip Erdogan University School of Medicine in the Department of ChestDiseases. The concentrations of pleural copeptin and typical pleural and serum marker levels were measured in 76 subjects withpleural effusions including 22 transudates caused by congestive heart failure (CHF), and 54 exudates including 18 parapneumonic(PPE), 18 tuberculous pleural effusions (TBPEs), 18 malignant effusions (MPEs).Results: Median pleural fluid copeptin levels were higher in exudates than in transudates (1936 ng/mL and 1313 pg/mL, p value

Özet

Giriş: Copeptin, arjinin-vazopressin ile birlikte farklı uyarılar sonucu nörohipofizden e ş zamanlı olarak salın ır. Fizyolojik fonksiyonuhala net de ğildir. Copeptinin artm ış kan düzeyleri birçok hastalıkta kötü prognozla iliş kilidir. Plevral sıvı, sık karşıla şılan klinik birdurumdur. En sık nedenleri; kalp yetmezliği, parapnömonik efüzyon, kanser ve pulmoner embolidir. Tüberküloz, geliş mekte olanülkelerde plevral efüzyonun diğer önemli nedenlerinden birisidir. Çalışmadaki amacım ız yeni bir biyobelirteç olan copeptinin plevralefüzyona neden olan farklı hastalıkların ayırım ındaki etkisini ara ştırmaktır.Materyal ve Metod: Çalışma Recep Tayyip Erdo ğan Üniversitesi T ıp Fakültesi Gö ğüs Hastalıkları Anabilim Dalında yapıldı. Çalış maya22 kalp yetmezliği, 18 parapnömonik efüzyon (PPE), 18 kanser ve 18 tüberküloza ba ğlı plevral s ıvısı olan toplam 76 hasta alındı. Buhastaların plevral s ıv ısında ELISA yöntemiyle copeptin düzeyi ölçüldü.Bulgular: Eksüda özelliğinde plevral sıvı nedenleri olan PPE, tüberküloz ve kanserde copeptin düzeyleri arasında anlamlı farklılıktespit edilmedi. Sırasıyla copeptin düzeyleri; 1979 ng/mL (1016-3386), 2019 ng/mL (1129-3204) ve 1769 ng/mL (961-2902). Ancakbu üç gruptaki copeptin düzeyileri, trasüdal plevral efüzyon nedeni plan kalp yetmezliğinden [(1313 pg/mL (891-1814)] anlamlıolarak yüksek bulundu (p< 0.001). Eksüdal sıvı nedenleri olan PPE, tüberküloz ve kanserden olu şan toplam 54 hasta tek grup altın-da birle ştirilerek, kalp yetmezliğiyle karşıla ş tırıldı. Copeptin düzeyinin, eksüdal s ıvıda transüdal sıvıya göre anlamlı yüksek oldu ğugörüldü. Sırasıyla copeptin düzeyleri; 1936 ng/mL (961-3386) ve 1313 pg/mL (891-1814) (p< 0.001). ROC-curve analiziyle copep-tin için cut-off de ğeri 1469 ng/mL kabul edildiğinde, eksüdayı transüdadan %79.6 sensitivite, %8.8 spesifiteyle ay ırabildiği tespitedildi.Sonuç: Plevral copeptin düzeyi, eksüdayı transüdadan ayırt etme özelliği ta şıyan yeni bir biyobelirteçtir. Ancak bu özelliği plevral sıvıprotein ve laktat dehidrogenaz düzeyinden daha dü şüktür. Rutin kullan ımda önerilmesi mümkün gözükmemektedir. Plevral copeptindüzeyinin sık eksüdal sıvı nedenleri olan PPE, tüberküloz ve kanser ayırım ında katkısı yoktur.

🔖

Cite This Article

ÇINARKA, H., GÜMÜŞ, A., KARATAŞ, M., ŞAHİN, Ü., KAYHAN, S., KIRBAŞ, A. (2022). Elevated pleural copeptin levels can distinguish to exudate from transudates. Tüberküloz ve Toraks, Cilt: 62 - Sayı: 4, 267–272. https://ajindex.com/articles/618616

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Barat C, Simpson L, Breslow E. Properties of human vaso- press in precurs or constructs: inefficient monomerfolding in the absence of copeptin as a potential contributor to diabetes insipidus. Biochemistry 2004;43:8191-203
  2. Stolz D, Christ-Crain M, Morgenthaler NG, Leuppi J, Miedinger D, Bingisser R, et al. Copeptin, C-reactive pro- tein, and procalcitonin as prognostic biomarkers in acute exacerbation of COPD. Chest 2007;131:1058-67
  3. Muller B, Morgenthaler N, Stolz D, Schuetz P, Muller C, Bingisser R, et al. Circulating levels of copeptin, a novel biomarker, in lower respiratory tract infections. Eur J Clin Invest 2007;37:145-52
  4. Seligman R, Papassotiriou J, Morgenthaler NG, Meisner M, Teixeira PJ. Copeptin, a novel prognostic biomarker in ventilator-associated pneumonia. Crit Care 2008;12(1):R11
  5. Morgenthaler NG, Muller B, Struck J, Bergmann A, Redl H, Christ- Crain M. Copeptin, a stable peptide of the arginine vasopressin precursor, Is elevated in hemorrhagic and sep- tic shock. Shock 2007;28:219-26
  6. Stoiser B, Mörtl D, Hülsmann M, Berger R, Struck J, Morgenthaler NG, et al. Copeptin, a fragment of the vaso- pressin precursor, as a novel predictor of outcome in heart failure. Eur J Clin Invest 2006;36:771-8
  7. Voors AA, Von Haehling S, Anker SD, Hillege HL, Struck J, Hartmann O, et al. C-terminal provaso pressin (copeptin) is a strong prognostic marker in patients with heart failure after an acute myocardial infarction: results from the OPTIMAAL study. Eur Heart J 2009;30:1187-94
  8. Katan M, Fluri F, Morgenthaler NG, Schuetz P, Zweifel C, Bingisser R, et al. Copeptin: a novel, independent prognos- tic marker in patients with is chemic stroke. Ann Neurol 2009;66:799-808
  9. Light RW, Mac Gregor MI, Luchsinger PC, Ball WC Jr. Pleural effusions: the diagnostic seperation of transudates andexudates. Ann Intern Med 1972;77:507-13
  10. Light RW. Diagnostic principles in pleural disease. Eur Respir J 1997;10:476-81
  11. Metinta ş M. Plevral sıv ılı hastan ın de ğerlendirilmesi. Özlü T, Metinta ş M, Karada ğ M, Kaya A (editör). Solunum Sistemi Hastalıkları. İstanbul: İstanbul T ıp Kitabevi, 2010:1951-8
  12. Light RW. Pleural Diseases. 5 th Ed. New York: Lippincott Williams and Wilkins; 2007
  13. World Health Organization. Global Tuberculosis Control- WHO Report 2012. Geneva, Switzerland
  14. Mehta AA, Gupta AS, Ahmed S, Rajesh V. Diagnostic util- ity of adenosine deaminase in exudative pleural effusions. Lung India 2014;31:142-4
  15. Metinta